Denali Therapeutics Inc. (DNLI)
DNLI trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1714899/000171489926000021/0001714899-26-000021-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | DNLI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2017 |
| SEC CIK | 0001714899 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$512.5M |
| Operating income | -$555.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $205.3M |
| Total assets | $1.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $102.9M cash; operating cash flow -$111.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 160,290,546 (2026-10-28); 146,661,833 a year earlier; 138,196,848 three years earlier. | Cover page 2026-10-28 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $1.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $17.8M | $70.1M | -$117.4M | $102.9M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $3.6M | -$127.6M | -$97.0M | $201.5M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | Not filed | -$128.4M | -$131.2M | $387.6M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $0 | -$128.5M | -$98.5M | $205.3M | No debt tags | $0 | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $0 | -$126.9M | -$107.3M | $91.0M | No debt tags | Needs four quarters | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $0 | -$124.1M | -$75.3M | $141.2M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | Not filed | -$133.0M | -$131.5M | $56.9M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $0 | -$114.8M | -$83.7M | $175.0M | No debt tags | $0 | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-10 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy DEFA14A ADDITIONAL MATERIALS | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 790 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -6.6% |
| 1 month | +1.8% |
| 3 months | -24.5% |
| Year to date | +13.5% |
| 1 year | +9.3% |
| From 52-week high | -31.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VCEL | Vericel Corporation | $57.48 | +0.91% | $2.9B |
| ADMA | ADMA Biologics Inc | $13.47 | -1.54% | $3.0B |
| IOVA | Iovance Biotherapeutics Inc. | $7.55 | -2.71% | $3.5B |
| RLAY | Relay Therapeutics Inc. | $17.27 | -4.53% | $3.8B |
| BEAM | Beam Therapeutics Inc. | $20.94 | -8.28% | $2.2B |
| TARS | Tarsus Pharmaceuticals Inc. | $78.68 | -1.99% | $3.9B |
| CRSP | CRISPR Therapeutics AG Common Shares | $40.37 | -4.43% | $3.9B |
| REPL | Replimune Group Inc. | $21.41 | -2.19% | $2.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier